X
[{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carmell Therapeutics Receives IND Clearance for CT-101, Bone Healing Accelerant","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Carmell Therapeutics"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants Carmell Therapeutics Expedited Review for CT-101, Bone Healing Accelerant","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Carmell Therapeutics"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Publication of Results From Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Heron Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics\u2019 Allogeneic Cell Therapy Product, Allob, Shows 90% Fusion Rate at 24 Months in Phase II A Studyinn Lumbar Spinal Fusion","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"$14.2 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics, Catalent Ink Pact to Streamline Production of Allogeneic Cell Therapy Product, ALLOB","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Pharma Completes Acquisition of Bone Therapeutics\u2019 Cell Therapy Manufacturing Subsidiary Skeletal Cell Therapy Support","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Allay Therapeutics"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Janssen Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Bristol Myers Squibb"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"PRC Clinical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Biorestorative Therapies"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Secures EUR 5 Million Financing","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Signs Definitive Subscription Agreement for A Maximum of EUR 5M Convertible Bonds Facility With ABO","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Biorestorative Therapies"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces First Patient Enrolled for the Company\u2019s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Biorestorative Therapies"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Optimizes Statistical Analysis and Introduces Interim Analysis in The Ongoing ALLOB Phase IIb Study for High-Risk Tibial Fractures","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Medsenic","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"$5.0 million","newsHeadline":"Bone Therapeutics to Broaden and Derisk Therapeutic Portfolio by Acquiring Majority Participation in Medsenic","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Medsenic"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Pregene","pharmaFlowCategory":"D","amount":"$53.6 million","upfrontCash":"$9.7 million","newsHeadline":"Bone Therapeutics to Regain Worldwide Rights to ALLOB","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Alpha Healthcare Acquisition Corp.","pharmaFlowCategory":"D","amount":"$154.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Healthcare Acquisition Corp. III Announces Merger with Carmell Therapeutics, a Phase 2 Stage Biotechnology Platform Company Developing Allogeneic Plasma-based Biomaterials for Bone and Soft Tissue Healing Indications","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Carmell Therapeutics"}]
Find Drugs for Orthopedics/Orthopedic Surgery in Phase II Clinical Development
Filters
×
FILTER:
Company
Sponsor
Country
Product Type
News Type
Details:
Carmell Therapeutics is in early preclinical testing of BHA product as an orthobiolgoic to determine the capability of BHA to act as an enhancer to existing bone graft substitutes as well as a stand-alone new alternative to bone graft substitute products.
Lead Product(s):
Allogeneic Plasma-based Biomaterial,Calcium Phosphate
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BHA
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Alpha Healthcare Acquisition Corp.
Deal Size: $154.0 millionUpfront Cash: Undisclosed
Deal Type: MergerJanuary 04, 2023
Details:
ALLOB (allogeneic bone cell therapy) is an allogeneic osteoblastic cell therapy product derived from ex vivo cultured bone marrow cells. It represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells into bone-forming cells.
Lead Product(s):
Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Pregene
Deal Size: $53.6 millionUpfront Cash: $9.7 million
Deal Type: TerminationOctober 07, 2022
Details:
Bone Therapeutics would also issue and automatically allot one subscription right to each outstanding share of Bone Therapeutics, in case of statistically positive interim results of the ALLOB Phase IIb trial.
Lead Product(s):
Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Bone Therapeutics
Deal Size: $5.0 millionUpfront Cash: $5.0 million
Deal Type: AcquisitionAugust 10, 2022
Details:
ALLOB (allogeneic bone cell therapy) represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells.
Lead Product(s):
Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableJuly 15, 2022
Details:
BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow, is to be injected by a physician into the patient’s damaged disc to Treat Chronic Lumbar Disc Disease.
Lead Product(s):
BRTX-100
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BRTX-100
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableJune 30, 2022
Details:
BRTX-100 is a novel product to treat damaged, degenerating discs, an autologous stem cell product to treat persistent lower back pain due to painful degenerative discs.
Lead Product(s):
BRTX-100
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BRTX-100
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableJune 22, 2022
Details:
The proceeds of the financing will contribute to continuing to advance the clinical development of Bone Therapeutics’ lead asset, its allogeneic bone cell therapy, ALLOB.
Lead Product(s):
Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
ABO Securities
Deal Size: $5.4 millionUpfront Cash: Undisclosed
Deal Type: AgreementMay 31, 2022
Details:
The proceeds of the financing will be used to advance the clinical development of Bone Therapeutics’ lead asset, the allogeneic bone cell therapy, ALLOB.
Lead Product(s):
Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
ABO Securities
Deal Size: $5.4 millionUpfront Cash: Undisclosed
Deal Type: FinancingApril 12, 2022
Details:
Pursuant to the agreement, PRC Clinical will manage BioRestorative’s Phase 2 clinical study of BRTX-100, the Company’s lead clinical product to treat chronic lumbar disc disease.
Lead Product(s):
Hypoxic Cultured Mesenchymal Stem Cells
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BRTX-100
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
PRC Clinical
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: AgreementDecember 21, 2021
Details:
Milvexian demonstrated efficacy and no increase in bleeding across doses, when compared with enoxaparin, for postoperative venous thromboembolism (VTE) prevention in patients undergoing elective total knee replacement (TKR) surgery.
Lead Product(s):
Milvexian
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: JNJ-70033093
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator:
Janssen Pharmaceutical
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableNovember 15, 2021
Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
